<qa>  What is the primary goal of the trial?The trial enrolls patients with moderate to severe Hidradenitis Suppurativa HS. The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints e.g., Hidradenitis Suppurativa Clinical Response HiSCR, Dermatology Life Quality Index DLQI, Visual Analog Scale VAS for disease, VAS for pain, Hidradenitis Suppurativa - Physicians Global Assessment HS-PGA, Modified Sartorius Score mSS. 